accueil

Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of over 40 professionals from all over Europe, the U.S., and Asia. 

The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed over 500 companies over five decades, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.

Sofinnova Partners invest in start-ups, early-stage companies, corporate spin-offs, and occasionally turnaround situations. The firm invests in Life Sciences (Biopharmaceuticals / Biotech, Medical Devices, Industrial Biotechnology). Sofinnova Partners proactively sources deals, takes a lead role, is most often the first institutional investor in Round A financings, and leads its portfolio companies until exit. The firm's partners sit on the boards of its portfolio companies and play an active role in the formation phase alongside entrepreneurs. Sofinnova Partners invests throughout Europe from its headquarters in Paris with a portion of investments made in the rest of the world.

View More

September 17, 2020 – Paris, France   Gradient Denervation Technologies, a Paris-based medical device company developing a minimally-invasive solution for the treatment of pulmonary hypertension, announced today the close of a €3.5M seed financing from Sofinnov...

HBM Healthcare Investments joins lead investor Sofinnova Partners and New Enterprise Associates in consortium   September 16, 2020 01:30 AM Eastern Daylight Time BASEL, Switzerland--(BUSINESS WIRE)--Polyneuron Pharmaceuticals AG, a clinical stage developer of ...

Recognition of Biotalys’ unique protein-based biocontrol solutions for food protection   GHENT, Belgium and RESEARCH TRIANGLE PARK, N.C., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Biotalys NV, a transformative food and crop protection company, today announced that it...

Redx will lead discovery and preclinical development activities on two cancer targets

STOCKHOLM, Aug. 13, 2020 /PRNewswire/ -- Transaction adds late-stage orphan pipeline asset and platform in inflammation and fibrosis. Calliditas to acquire 62.7% of Genkyotex for €20.3M in cash at €2.80 per share in an off-market transaction. Following the clo...

Henrijette Richter

Henrijette Richter

Managing Partner

MEET OUR TEAM